Welcome to our dedicated page for Fortress Biotech news (Ticker: FBIO), a resource for investors and traders seeking the latest updates and insights on Fortress Biotech stock.
Fortress Biotech, Inc. operates a biopharmaceutical business built around acquiring and advancing pharmaceutical and biotechnology assets. Company updates commonly cover product revenue, equity holdings, dividend and royalty income, FDA decisions, subsidiary transactions and clinical or regulatory progress across its portfolio.
Recurring news also includes Journey Medical dermatology products, Cyprium Therapeutics and ZYCUBO® for Menkes disease, priority review voucher monetization and corporate financial results. Fortress reports material developments involving approved prescription products, portfolio-company ownership, royalties, capital resources and business-development activity.
Journey Medical Corporation (DERM)/b) will participate in two investor conferences in September 2026.Co-Founder, President and CEO Claude Maraoui is scheduled for the Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference on Thursday, September 10, 2026, in New York City in a 1x1 meetings format. He is also scheduled for the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026, at 10:00 a.m. ET, also in New York City, featuring a presentation and 1x1 meetings.
A webcast of the H.C. Wainwright presentation will be available on the News and Events page of the Investors section of Journey Medical’s website for approximately 30 days after the meeting.
Fortress Biotech (FBIO) will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. Chairman, President and CEO Lindsay A. Rosenwald, M.D., is scheduled to deliver the presentation, which will be available for on-demand viewing to conference attendees starting Friday, September 11, 2026, at 7:00 a.m. ET.
Fortress will also participate in one-on-one meetings during the conference, which takes place September 14–16, 2026. The company highlights a portfolio of marketed prescription products and development programs across oncology, dermatology and rare diseases, advanced through majority-owned entities and minority holdings, and supported by partnerships with leading academic and biopharmaceutical organizations.
Fortress Biotech (Nasdaq: FBIO) reported second quarter 2026 net revenue of $18.7 million, up about 14% from $16.4 million a year earlier, driven largely by $17.8 million in dermatology product sales at Journey Medical. Consolidated cash and cash equivalents rose to $196.6 million at June 30, 2026, from $79.4 million at year-end 2025, helped by prior ZYCUBO® priority review voucher monetization.
Research and development expense declined to $0.8 million and selling, general and administrative costs to $20.8 million, down sharply year over year. Net loss attributable to common stockholders was $(2.5) million, or $(0.08) per share, versus net income of $13.4 million in the prior-year quarter. Partnered programs advanced, including Crystalys’ $130 million Series B to fund dotinurad Phase 3 development, new royalties from ZYCUBO® and UNLOXCYT™, and AstraZeneca’s subgroup data for anselamimab showing a 62% survival improvement and 71% reduction in cardiovascular hospitalizations in kappa AL amyloidosis.
Journey Medical (Nasdaq: DERM) reported second quarter 2026 total revenue of $18.5 million, up 23% from $15.0 million a year earlier, driven by Emrosi® revenue of $8.1 million. Gross margin was 67%, unchanged year over year, and selling, general and administrative expenses declined to $10.9 million, down $1.0 million.
GAAP net loss narrowed to $0.3 million, or $(0.01) per share, versus a $3.8 million loss, or $(0.16) per share, in 2025. Non-GAAP Adjusted EBITDA turned positive at $2.9 million for the quarter. Cash and cash equivalents were $25.6 million at June 30, 2026, compared with $24.1 million at year-end 2025. Emrosi® total prescriptions reached about 36,000 in Q2 2026, versus 30,000 in Q1 2026.
Journey Medical (Nasdaq: DERM) will release its second quarter 2026 financial results after U.S. markets close on Wednesday, August 12, 2026. Management will host a conference call and live audio webcast the same day at 4:30 p.m. ET to discuss results and provide a corporate update.
U.S. participants can dial 1-866-777-2509, international participants 1-412-317-5413, or register online to receive dial-in details. The webcast will be available via the Investors section of Journey Medical’s website and remain accessible for approximately 30 days after the call.
Fortress Biotech (Nasdaq: FBIO) and subsidiary Urica Therapeutics reported that Crystalys Therapeutics, in which Urica holds an equity stake, closed an oversubscribed $130 million Series B financing. The capital is intended to fund late-stage global clinical development and commercialization preparation of dotinurad, a once-daily oral URAT1 inhibitor for gout.
Dotinurad’s program includes two ongoing Phase 3 registration-directed trials, RUBY and TOPAZ, and the ongoing Phase 2 AMETHYST study across a broad gout population. According to Fortress, the financing is expected to provide Crystalys operational runway through multiple anticipated clinical and regulatory milestones and indirectly benefits Fortress via Urica’s minority equity position in Crystalys and eligibility for a 3% royalty on future net sales of dotinurad.
Journey Medical (Nasdaq: DERM) announced that Co-Founder, President and CEO Claude Maraoui will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference on May 20, 2026. The virtual session is scheduled for 5:00 p.m. ET, with registration via the A.G.P. conference link.
Fortress Biotech (Nasdaq: FBIO) announced that Chairman, President and CEO Lindsay A. Rosenwald, M.D., will join a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference on Wednesday, May 20, 2026, starting at 12:20 p.m. ET. Conference registration is available via A.G.P.’s online registration link.
Fortress Biotech (Nasdaq: FBIO) reported first quarter 2026 net income attributable to common stockholders of $108.4 million, or $3.44 basic and $2.82 diluted EPS, versus a prior-year loss. Consolidated revenue was $16.0 million, mainly from Journey Medical.
Cash and cash equivalents rose to $255.8 million, helped by Cyprium’s $205 million sale of a Priority Review Voucher, while Oaktree loan principal fell to $15.0 million. The FDA approved ZYCUBO for Menkes disease, creating new royalty and milestone opportunities alongside UNLOXCYT and Emrosi.
Journey Medical (Nasdaq: DERM) reported first quarter 2026 revenue of $16.0 million, up 21% year-over-year. Emrosi® revenue rose to $6.3 million. Gross margin was 61.0%, including a $1.3 million non-recurring non-cash inventory write-down.
Net loss narrowed to $2.2 million, while Adjusted EBITDA turned positive at $0.6 million. Cash and equivalents increased to $27.2 million. Emrosi® prescriptions reached 29,968, and a new GPO contract expands access to about 85% of U.S. commercial lives.